Tedatioxetine

Tedatioxetine

Tedatioxetine
Systematic (IUPAC) name
4-{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine
Clinical data
Legal status
  • Investigational
Identifiers
CAS number  YesY
ATC code None
PubChem
ChemSpider  YesY
KEGG  N
Synonyms Lu AA24530; Lu-AA-24530
Chemical data
Formula C18H21NS 
Mol. mass 283.43 g/mol
 N   

Tedatioxetine (Lu AA24530) is an antidepressant currently under development by Lundbeck and Takeda for the treatment of major depressive disorder (MDD).[1][2] Tedatioxetine is reported to act as a triple reuptake inhibitor (5-HT > NE > DA) and in addition as a 5-HT2A, 5-HT2C, 5-HT3 and α1A-adrenergic receptor antagonist.[3][4][5][6][7] It is currently in phase II clinical trials.[1]

See also

References

  1. ^ a b "Pipeline of Lundbeck". Retrieved 25 August 2013. 
  2. ^ "Search of: Lu AA24530 - List Results - ClinicalTrials.gov". 
  3. ^ "Patent US20100144788 - 4- [2- (4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistant depression or residual symptoms in depression". Retrieved 7 April 2014. 
  4. ^ Stephen M. Stahl (19 May 2008). Depression and bipolar disorder: Stahl's essential psychopharmacology. Cambridge University Press. p. 206.  
  5. ^ Ian P. Stolerman (30 August 2010). Encyclopedia of Psychopharmacology. Springer. p. 105.  
  6. ^ "Lu AA24530 shows positive results in major depressive disorder phase II study - FierceBiotech". 
  7. ^ "Future Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD -- Neurotransmitter.net". 

External links

  • Lu AA24530 shows positive results in major depressive disorder phase II study